» Articles » PMID: 35216428

The Unitary Micro-Immunotherapy Medicine Interferon-γ (4 CH) Displays Similar Immunostimulatory and Immunomodulatory Effects Than Those of Biologically Active Human Interferon-γ on Various Cell Types

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Feb 26
PMID 35216428
Authors
Affiliations
Soon will be listed here.
Abstract

As a cytokine, gamma-interferon (IFN-γ) is considered a key player in the fine-tuned orchestration of immune responses. The extreme cellular sensitivity to cytokines is attested by the fact that very few of these bioactive molecules per cell are enough to trigger cellular functions. These findings can, at least partially, explain how/why homeopathically-prepared cytokines, and especially micro-immunotherapy (MI) medicines, are able to drive cellular responses. We focused our fundamental research on a unitary MI preparation of IFN-γ, specifically employed at 4 CH, manufactured and impregnated onto sucrose-lactose pillules as all other MI medicines. We assessed the IFN-γ concentration in the medium after dilution of the IFN-γ (4 CH)-bearing pillules and we evaluated in vitro drug responses in a wide range of immune cells, and in endothelial cells. Our results showed that IFN-γ (4 CH) stimulated the proliferation, the activation and the phagocytic capabilities of primary immune cells, as well as modulated their cytokine-secretion and immunity-related markers' expression in a trend that is quite comparable with the well-recognized biological effects induced by IFN-γ. Altogether, these data provide novel and additional evidences on MI medicines, and specifically when active substances are prepared at 4 CH, thus suggesting the need for more investigations.

Citing Articles

Exploring the Potential of Micro-Immunotherapy in the Treatment of Periodontitis.

Ferra-Canellas M, Garcia-Sureda L Life (Basel). 2024; 14(5).

PMID: 38792574 PMC: 11122531. DOI: 10.3390/life14050552.


The Micro-Immunotherapy Medicine 2LPAPI Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells.

Jacques C, Marchand F, Chatelais M, Albinet V, Coustal C, Floris I Cancers (Basel). 2024; 16(7).

PMID: 38611099 PMC: 11010933. DOI: 10.3390/cancers16071421.


In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy.

Jacques C, Marchand F, Chatelais M, Brulefert A, Riffault M, Floris I Life (Basel). 2024; 14(3).

PMID: 38541700 PMC: 10971188. DOI: 10.3390/life14030375.


Actives from the Micro-Immunotherapy Medicine 2LMIREG Reduce the Expression of Cytokines and Immune-Related Markers Including Interleukin-2 and HLA-II While Modulating Oxidative Stress and Mitochondrial Function.

Jacques C, Marchand F, Chatelais M, Floris I J Inflamm Res. 2024; 17:1161-1181.

PMID: 38406323 PMC: 10894519. DOI: 10.2147/JIR.S445053.


Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV Active Ingredients.

Jacques C, Marchand F, Chatelais M, Brulefert A, Floris I Life (Basel). 2024; 14(1).

PMID: 38255717 PMC: 10821216. DOI: 10.3390/life14010102.


References
1.
Lilli N, Revy D, Robelet S, Lejeune B . Effect of the micro-immunotherapy medicine 2LPARK on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson's disease. Degener Neurol Neuromuscul Dis. 2019; 9:79-88. PMC: 6635836. DOI: 10.2147/DNND.S202966. View

2.
Liddiard K, Welch J, Lozach J, Heinz S, Glass C, Greaves D . Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol Biol. 2006; 7:45. PMC: 1698493. DOI: 10.1186/1471-2199-7-45. View

3.
Floris I, Rose T, Rojas J, Appel K, Roesch C, Lejeune B . Pro-Inflammatory Cytokines at Ultra-Low Dose Exert Anti-Inflammatory Effect In Vitro: A Possible Mode of Action Involving Sub-Micron Particles?. Dose Response. 2021; 18(4):1559325820961723. PMC: 7829609. DOI: 10.1177/1559325820961723. View

4.
Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J . Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999; 11(1):81-8. DOI: 10.1093/intimm/11.1.81. View

5.
Soza A, Heller T, Ghany M, Lutchman G, Liang T, Germain J . Pilot study of interferon gamma for chronic hepatitis C. J Hepatol. 2005; 43(1):67-71. DOI: 10.1016/j.jhep.2005.02.023. View